نتایج جستجو برای: thalidomide

تعداد نتایج: 3195  

Journal: :Haematologica 2006
Jean-François Abgrall Isabelle Guibaud Jean-Noël Bastie Michel Flesch Jean-François Rossi Laurence Lacotte-Thierry Françoise Boyer Philippe Casassus Borhane Slama Christian Berthou Philippe Rodon Michel Leporrier Bruno Villemagne Chantal Himberlin Kamel Ghomari Fabrice Larosa Florence Rollot Jacqueline Dugay Christian Allard Michel Maigre Françoise Isnard Robert Zerbib Jean-Michel Cauvin

BACKGROUND AND OBJECTIVES In non-randomized studies, thalidomide appeared to be effective in myeloid metaplasia with myelofibrosis (MMM). We compared thalidomide to placebo for treatment of anemia in MMM. DESIGN AND METHODS A prospective phase II B, randomized double-blind multicenter trial comparing thalidomide 400 mg/d with placebo for 180 days was conducted in 52 anemic patients (hemoglobi...

2017
Jianlin Qiao Yulu Wu Xiaoqing Wu Yun Liu Xiaoqian Li Wen Ju Kunming Qi Depeng Li Elizabeth E. Gardiner Robert K. Andrews Lingyu Zeng Kailin Xu

Increased risk of thromboembolism and platelet hyperreactivity has been reported in patients receiving thalidomide therapy. Whether thalidomide induces platelet activation directly or through other factors remains unclear. The aim of this study was to evaluate the effect of thalidomide on platelet activation under resting conditions in vitro and in vivo. Isolated human or mouse platelets were t...

2011
Ray Greek Niall Shanks Mark J. Rice

The current use of animals to test for potential teratogenic effects of drugs and other chemicals dates back to the thalidomide disaster of the late 1950s and early 1960s. Controversy surrounds the following questions: 1. What was known about placental transfer of drugs when thalidomide was developed? 2. Was thalidomide tested on animals for teratogenicity prior to its release? 3. Would more an...

Journal: :Haematologica 2012
Martin Kropff Honorata Giongco Baylon Jens Hillengass Tadeusz Robak Roman Hajek Peter Liebisch Stefan Goranov Cyrille Hulin Joan Bladé Tommaso Caravita Herve Avet-Loiseau Thomas M Moehler Claire Pattou Lela Lucy Elisabeth Kueenburg Axel Glasmacher Robert Zerbib Thierry Facon

BACKGROUND Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma. DESIGN AND METHODS We conducted an international, randomized, open-label, four-arm, phase III trial to compare three different doses of thalidomide (100, 200, or 400 mg/day) with standard dexamethas...

Journal: :Haematologica 2010
Marta Segarra Ester Lozano Marc Corbera-Bellalta Carme Vilardell Maria-Teresa Cibeira Jordi Esparza Nora Izco Joan Bladé Maria C Cid

BACKGROUND Thalidomide and its analogs are effective agents in the treatment of multiple myeloma. Since gelatinases (matrix metalloproteinases-2 and -9) play a crucial role in tumor progression, we explored the effect of thalidomide on gelatinase production by malignant B lymphoid cell lines. DESIGN AND METHODS We investigated the effect of therapeutic doses of thalidomide on integrin-mediate...

Journal: :Carcinogenesis 2004
Kathleen L DeCicco Takemi Tanaka Fausto Andreola Luigi M De Luca

Lung cancer is the leading cause of cancer-related death in developed countries. Non-small cell lung cancer (NSCLC) represents 80% of the total lung cancer cases and is comprised of adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma and large cell carcinoma (LCC) subtypes. The ability of LCC to metastasize earlier than the other forms of lung cancer suggests anti-angiogenic drugs ...

Journal: :Drug safety 2006
Kathleen Uhl Edward Cox Rose Rogan Jerome B Zeldis Dena Hixon Lesley-Anne Furlong Sarah Singer Tracy Holliman Joanne Beyer William Woolever

INTRODUCTION In 1998, thalidomide (Thalomid), a known human teratogen, was approved by the US FDA for the treatment of erythema nodosum leprosum. To prevent fetal exposure to thalidomide, a restricted distribution risk management programme, the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.), was implemented. All clinicians, pharmacists and patients who prescribe, dispense ...

Journal: :Drugs 2000
V Peuckmann M Fisch E Bruera

Thalidomide, after being banned from the market in the early 1960s because of the worldwide teratogenesis disaster, is currently being rediscovered because of its multiple therapeutic effects in various serious diseases and symptoms. Original studies examined the anxiolytic, mild hypnotic, anti-emetic and adjuvant analgesic properties of this drug. Subsequently, thalidomide was found to be high...

Journal: :Haematologica 2007
Philip T Murphy John Rory O'Donnell

Thalidomide has become an important agent in the treatment of myeloma. However, thalidomide induced erectile dysfunction is a serious complication which has received very little attention. In our hematology department, 6 out of 11 male patients developed erectile dysfunction (grade 3 in 5/6) within 4 weeks of starting thalidomide. Our results suggest that thalidomide induced impotence is a comm...

Journal: :The European respiratory journal 2006
Q Ye B Chen Z Tong S Nakamura R Sarria U Costabel J Guzman

Thalidomide exhibits diverse actions of anti-inflammation, immunomodulation and anti-angiogenesis. The efficacy of thalidomide treatment in sarcoidosis with lupus pernio is thought to be due to inhibition of tumour necrosis factor (TNF)-alpha. The mechanisms that underlie the properties of thalidomide are still unclear in interstitial lung disease. The current authors investigated the potential...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید